Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: A new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation

Immunohematology

Volumn 33, Issue 1, 2017, Pages 15-21

  Cooling, Laura L W ^a   Sherbeck, John ^b   Mowers, Jonathon C ^b   Hugan, Sheri L ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Anemia; Autoantibody; Checkpoint inhibitor; Cytopenia

Indexed keywords

CARBOPLATIN; CISPLATIN; ERYTHROCYTE ANTIBODY; ETOPOSIDE; IBUPROFEN; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; AUTOANTIBODY; AUTOANTIGEN; MONOCLONAL ANTIBODY; ALPRAZOLAM; B RAF KINASE INHIBITOR; CLINDAMYCIN; COLD AGGLUTININ; COLD AUTOANTIBODY; FOLIC ACID; HYDROCODONE; HYDROMORPHONE; IRON; LACTATE DEHYDROGENASE; METRONIDAZOLE; NON PRESCRIPTION DRUG; PARACETAMOL; TAMSULOSIN; UNCLASSIFIED DRUG; VEMURAFENIB; VERMURAFENIB; WARM AUTOANTIBODY;

ADULT; ANEMIA; APLASTIC ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL ARTICLE; COOMBS TEST; CYTOPENIA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; IMMUNE DYSREGULATION; LYMPHOCYTOPENIA; MALE; MEDICAL RECORD REVIEW; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RASH; RETROSPECTIVE STUDY; SMALL CELL LUNG CANCER; ADVERSE EFFECTS; AGED; ERYTHROCYTE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; ABSOLUTE LYMPHOCYTE COUNT; ADVERSE DRUG REACTION; ANTIBODY DETECTION; ARTHRITIS; BLOOD GROUP ABO SYSTEM; BLOOD GROUP RH; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DYSPNEA; FATIGUE; GENE MUTATION; HAND PAIN; INDIRECT ANTIGLOBULIN TEST; JOINT SWELLING; LEG DISEASE; LEUKOCYTE COUNT; LEUKOCYTE DIFFERENTIAL COUNT; MEAN CORPUSCULAR VOLUME; METASTASIS; MICROCYTIC ANEMIA; ONCOGENE C KIT; PATHOGENESIS; PHENOTYPE; PLATELET COUNT; PRURIGO; REVIEW; SKIN BLEEDING; SKIN ULCER; TRUNK;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; AUTOANTIGENS; ERYTHROCYTES; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 85021856414     PISSN: 0894203X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica 2013: Article ID 857519. dx.doi.org/10.1155/2013/857519
2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
3. Gao J, He Q, Subudhi S, et al. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene 2015;34:5411-7
4. Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 2016;375:143-53
5. Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 2015;37:764-82
6. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
7. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-20
8. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer. N Engl J Med 2015;373:123-35
9. National Institutes of Health, Clinical Trials Web site. Available at https://ClinicalTrials.gov/. Last accessed 8/29/2016
10. Li S, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol 2013;6:74
11. Gibson R, Delaune J, Szady A, Markham M. Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep 2016. doi:10.1136/bcr-2016-216228
12. Du Rusquec P, Saint-Jean M, Brocard A, et al. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. J Immunother 2014;37:348-50
13. Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 2009;58:1351-3
14. Simeone E, Grimaldi AM, Esposito A, et al. Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep 2014;8:240
15. Kong BY, Micklethwaite KP, Swaminathan S, Kefford RF, Carlino MS. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res 2016;26:202-4
16. Nair R, Gheith S, Nair SG. Immunotherapy-associated hemolytic anemia with pure red cell aplasia. N Engl J Med 2016;374:1096-7
17. Judd WJ, Johnson ST, Storry JR. Judd's methods in immunohematology. 3rd ed. Bethesda, MD: American Association of Blood Banks, 2008
18. Weldy L. Polyethylene glycol antiglobulin test (PEG-AGT). Immunohematology 2014:30:158-60
19. Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76:43-50
20. Sun J, Schiffman J, Raghunath A, Ng Tang D, Chen H, Sharma P. Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 2008;8:9
21. Von Euw E, Chodon T, Attar N, et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 2009;7:35
22. Ahmad E, Elgohary T, Ibrahim H. Naturally occurring regulatory T cells and interleukins 10 and 12 in the pathogenesis of idiopathic warm autoimmune hemolytic anemia. J Investig Allergol Clin Immunol 2011;21:297-304
23. Mqadmi A, Zheng X, Yazdanbakhsh K. CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia. Blood 2005;105:3746-8
24. Ward FJ, Hall AM, Cairns LS, et al. Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia. Blood 2008;111:680-7